Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG00012 versus interferon beta-1a in pediatric relapsing-remitting multiple sclerosis
2013-002318-11Phase 3Completed
- Sponsor
- Biogen
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dimethyl fumarate in multiple sclerosis (MS) (2 arms), sponsored by Biogen. Primary endpoint: Proportion of participants free of new/newly enlarging T2 hyperintense lesions at Week 96. Started Mar 2014; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-002318-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002318-11.